Karyopharm Therapeutics: A Cautious Hold Amid Steady Performance and Pipeline Uncertainties
HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target
Karyopharm Therapeutics Price Target Cut to $5.00/Share From $8.00 by Baird
Karyopharm Therapeutics Analyst Ratings
Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $5
Karyopharm Therapeutics (KPTI) Gets a Buy From RBC Capital
Buy Rating Affirmed for Karyopharm Therapeutics Amid Strong Q2 Performance and Positive Xpovio Sales Outlook
Barclays Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $5
Karyopharm Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $7
Karyopharm Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target
Barclays Remains a Buy on Karyopharm Therapeutics (KPTI)
Buy Rating for Karyopharm Therapeutics: Debt Restructuring and Promising Xpovio Studies Drive Optimistic Outlook
Karyopharm Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target
Optimistic Buy Rating for Karyopharm Therapeutics Amidst Financial Stability and Promising Clinical Trials
Karyopharm Therapeutics (KPTI) Gets a Buy From Barclays
Karyopharm Therapeutics (KPTI) Gets a Buy From Piper Sandler
Analysts Are Bullish on Top Healthcare Stocks: Ionis Pharmaceuticals (IONS), Intuitive Surgical (ISRG)